トップページ > 2011年の刊行論文

2011年の刊行論文

Cumulated List of Papers Published in 2011

Group for Cancer Development and Progression: 1. Division of Molecular Pathology; 2. Division of Genetics; 3. Division of Familial Cancer Research; 4. Division of Multistep Carcinogenesis; 5. Division of Virology; 6. Division of Cancer Development System

Group for Research of Molecular Functions and Targets: 7. Division of Metastasis and Invasion Signaling; 8. Division of Molecular and Cellular Medicine; 9. Division of Cancer Biology; 10. Division of Cancer Differentiation; 11. Division of Hematological Malignancy

Group for Development of Molecular diagnostics and Individualized Therapy: 12. Division of Pharmacogenomics; 13. Division of Pharmacoproteomics; 14. Division of Epigenomics; 15. Division of Genome Biology; 16. Division of Cancer Genomics

Group for Translational Research: 17. Division of Cancer Pathophysiology; 18. Division of Cancer Stem Cell; 19. Division of Gene and Immune Medicine; 20. Division of Genome Stability Research; 21. Division of Chemotherapy and Clinical Research

Core Facilities for Research and Innovative Medicine: 22. Central Animal Division; 23. Central Radioisotope Division; 24. Core Facility Division

Project Group: 25. Division of Refractory Cancer Research; 26. Division of Cancer Prevention Research; 27. Division of Integrative Omics and Bioinformatics

1. Division of Molecular Pathology

1. Arai E, Kanai Y. Genetic and epigenetic alterations during renal carcinogenesis. Int J Clin Exp Pathol, 4:58-73, 2011

2. Arai E, Wakai-Ushijima S, Fujimoto H, Hosoda F, Shibata T, Kondo T, Yokoi S, Imoto I, Inazawa J, Hirohashi S, Kanai Y. Genome-wide DNA methylation profiles in renal tumors of various histological subtypes and non-tumorous renal tissues. Pathobiology, 78:1-9, 2011

3. Fujiwara H, Sekine S, Onaya H, Shimada K, Mikata R, Arai Y. Ring-like enhancement of focal nodular hyperplasia with hepatobiliary-phase Gd-EOB-DTPA-enhanced magnetic resonance imaging: radiological-pathological correlation. Jpn J Radiol, 29:739-743, 2011

4. Gotoh M, Arai E, Wakai-Ushijima S, Hiraoka N, Kosuge T, Hosoda F, Shibata T, Kondo T, Yokoi S, Imoto I, Inazawa J, Kanai Y. Diagnosis and prognostication of ductal adenocarcinomas of the pancreas based on genome-wide DNA methylation profiling by bacterial artificial chromosome array-based methylated CpG island amplification. J Biomed Biotechnol, 2011

5. Hayashi T, Horiuchi A, Sano K, Hiraoka N, Kanai Y, Shiozawa T, Tonegawa S, Konishi I. Molecular approach to uterine leiomyosarcoma: LMP2-deficient mice as an animal model of spontaneous uterine leiomyosarcoma. Sarcoma, 2011:476498, 2011

6. Hayashi T, Horiuchi A, Sano K, Hiraoka N, Kasai M, Ichimura T, Nagase S, Ishiko O, Shiozawa T, Kanai Y, Yaegashi N, Aburatani H, Tonegawa S, Konishi I. Involvement of proteasome β1i subunit, LMP2, on development of uterin uterine leiomyosarcoma. N A J Med Sci, 3:394-399, 2011

7. Hayashi T, Horiuchi A, Sano K, Hiraoka N, Kasai M, Ichimura T, Sudo T, Tagawa Y, Nishimura R, Ishiko O, Kanai Y, Yaegashi N, Aburatani H, Shiozawa T, Konishi I. Potential role of LMP2 as tumor-suppressor defines new targets for uterine leiomyosarcoma therapy. Sci Rep, 1:180, 2011

8. Hiraoka N, Yamazaki-Itoh R, Ino Y, Mizuguchi Y, Yamada T, Hirohashi S, Kanai Y. CXCL17 and ICAM2 are associated with a potential anti-tumor immune response in early intraepithelial stages of human pancreatic carcinogenesis. Gastroenterology, 140:310-321, 2011

9. Koyama T, Sekine S, Taniguchi H, Tsuda H, Ikegami M, Hano H, Kushima R. Hepatocyte nuclear factor 4A expression discriminates gastric involvement by metastatic breast carcinomas from primary gastric adenocarcinomas. Hum Pathol, 42:1777-1784, 2011

10. Lohr J, Ratliff T, Huppertz A, Ge Y, Dictus C, Ahmadi R, Grau S, Hiraoka N, Eckstein V, Ecker RC, Korff T, von Deimling A, Unterberg A, Beckhove P, Herold-Mende C. Effector T-Cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-β. Clin Cancer Res, 17:4296-4308, 2011

11. Nagashio R, Arai E, Ojima H, Kosuge T, Kondo Y, Kanai Y. Carcinogenetic risk estimation based on quantification of DNA methylation levels in liver tissue at the precancerous stage. Int J Cancer, 129:1170-1179, 2011

12. Nishiyama N, Arai E, Nagashio R, Fujimoto H, Hosoda F, Shibata T, Tsukamoto T, Yokoi S, Imoto I, Inazawa J, Kanai Y. Copy number alterations in urothelial carcinomas: their clinicopathological significance and correlation with DNA methylation alterations. Carcinogenesis, 32:462-469, 2011

13. Sekine S, Ogawa R, Kanai Y. Hepatomas with activating Ctnnb1 mutations in ‘Ctnnb1-deficient’ livers: a tricky aspect of a conditional knockout mouse model. Carcinogenesis, 32:622-628, 2011

14. Sekine S, Ogawa R, Ojima H, Kanai Y. Overexpression of α-methylacyl-CoA racemase is associated with CTNNB1 mutations in hepatocellular carcinomas. Histopathology, 58:712-719, 2011

15. Sekine S, Ogawa R, Ojima H, Kanai Y. Expression of SLCO1B3 is associated with intratumoral cholestasis and CTNNB1 mutations in hepatocellular carcinoma. Cancer Sci, 102:1742-1747, 2011

16. Shimada K, Nara S, Esaki M, Sakamoto Y, Kosuge T, Hiraoka N. Intrapancreatic nerve invasion as a predictor for recurrence after pancreaticoduodenectomy in patients with invasive ductal carcinoma of the pancreas. Pancreas, 40:464-468, 2011

17. Shimarda K, Nara S, Esaki M, Sakamoto Y, Kosuge T, Hiraoka N. Extended right hemihepatectomy for gallbladder carcinoma involving the hepatic hilum. Br J Surg, 98:117-123, 2011

18. Tsuboi S, Sutoh M, Hatakeyama S, Hiraoka N, Habuchi T, Horikawa Y, Hashimoto Y, Yoneyama T, Mori K, Koie T, Nakamura T, Saitoh H, Yamaya K, Funyu T, Fukuda M, Ohyama C. A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans. EMBO J, 30:3173-3185, 2011

2. Division of Genetics

19. Aoyagi K, Minashi K, Igaki H, Tachimori Y, Nishimura T, Hokamura N, Ashida A, Daiko H, Ochiai A, Muto M, Ohtsu A, Yoshida T, Sasaki H. Artificially induced epithelial-mesenchymal transition in surgical subjects: its implications in clinical and basic cancer research. PLoS One, 6:e18196, 2011

20. Arao T, Matsumoto K, Furuta K, Kudo K, Kaneda H, Nagai T, Sakai K, Fujita Y, Tamura D, Aomatsu K, Koizumi F, Nishio K. Acquired drug resistance to vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor in human vascular endothelial cells. Anticancer Res, 31:2787-2796, 2011

21. Kodera Y, Katanasaka Y, Kitamura Y, Tsuda H, Nishio K, Tamura T, Koizumi F. Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3. Breast Cancer Res, 13:R66, 2011

22. Konuma T, Nakamura S, Miyagi S, Negishi M, Chiba T, Oguro H, Yuan J, Mochizuki-Kashio M, Ichikawa H, Miyoshi H, Vidal M, Iwama A. Forced expression of the histone demethylase Fbxl10 maintains self-renewing hematopoietic stem cells. Exp Hematol, 39:697-709.e5., 2011

23. Michishita M, Akiyoshi R, Yoshimura H, Katsumoto T, Ichikawa H, Ohkusu-Tsukada K, Nakagawa T, Sasaki N, Takahashi K. Characterization of spheres derived from canine mammary gland adenocarcinoma cell lines. Res Vet Sci, 91:254-260, 2011

24. Nishio M, Yamanaka T, Matsumoto K, Kimura H, Sakai K, Sakai A, Sone T, Horiike A, Koizumi F, Kasahara K, Ohira T, Ikeda N, Saijo N, Arao T, Nishio K. Serum heparan sulfate concentration is correlated with the failure of epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with lung adenocarcinoma. J Thorac Oncol, 6:1889-1894, 2011

25. Oue N, Noguchi T, Anami K, Sentani K, Sakamoto N, Uraoka N, Wakamatsu Y, Sasaki H, Yasui W. Serum concentration and expression of Reg IV in patients with esophageal cancer: age-related elevation of serum reg IV concentration. Oncol Lett, 2:235-239, 2011

26. Saeki N, Saito A, Choi IJ, Matsuo K, Ohnami S, Totsuka H, Chiku S, Kuchiba A, Lee YS, Yoon KA, Kook MC, Park SR, Kim YW, Tanaka H, Tajima K, Hirose H, Tanioka F, Matsuno Y, Sugimura H, Kato S, Nakamura T, Nishina T, Yasui W, Aoyagi K, Sasaki H, Yanagihara K, Katai H, Shimoda T, Yoshida T, Nakamura Y, Hirohashi S, Sakamoto H. A functional single nucleotide polymorphism in mucin 1, at chromosome 1q22, determines susceptibility to diffuse-type gastric cancer. Gastroenterology, 140:892-902, 2011

27. Sato Y, Yamamoto N, Kunitoh H, Ohe Y, Minami H, Laird NM, Katori N, Saito Y, Ohnami S, Sakamoto H, Sawada JI, Saijo N, Yoshida T, Tamura T. Genome-wide association study on overall survival of advanced non-small cell lung cancer patients treated with carboplatin and paclitaxel. J Thorac Oncol, 6:132-138, 2011

28. Shibata K, Arai M, Matsuura M, Uno K, Yoshida T, Momose T, Ohtomo K. Relationship of detection rate of PET cancer screening examinees and risk factors: analysis of background of examinees. Ann Nucl Med, 25:261-267, 2011

29. Wang K, Diskin SJ, Zhang H, Attiyeh EF, Winter C, Hou C, Schnepp RW, Diamond M, Bosse K, Mayes PA, Glessner J, Kim C, Frackelton E, Garris M, Wang Q, Glaberson W, Chiavacci R, Nguyen L, Jagannathan J, Saeki N, Sasaki H, Grant SFA, Iolascon A, Mosse YP, Cole KA, Li H, Devoto M, McGrady PW, London WB, Capasso M, Rahman N, Hakonarson H, Maris JM. Integrative genomics identifies LMO1 as a neuroblastoma oncogene. Nature, 469:216-220, 2011

30. Yuan J, Takeuchi M, Negishi M, Oguro H, Ichikawa H, Iwama A. Bmi1 is essential for leukemic reprogramming of myeloid progenitor cells. Leukemia, 25:1335-1343, 2011

3. Division of Familial Cancer Research

31. Shimazu S, Nagamura Y, Yaguchi H, Ohkura N, Tsukada T. Correlation of mutant menin stability with clinical expression of multiple endocrine neoplasia type 1 and its incomplete forms. Cancer Sci, 102:2097-2102, 2011

4. Division of Multistep Carcinogenesis

32. Akca H, Demiray A, Tokgun O, Yokota J. Invasiveness and anchorage independent growth ability augmented by PTEN inactivation through the PI3K/AKT/NFkB pathway in lung cancer cells. Lung Cancer, 2011

33. Iwakawa R, Kohno T, Kato M, Shiraishi K, Tsuta K, Noguchi M, Ogawa S, Yokota J. MYC amplification as a prognostic marker of early-stage lung adenocarcinoma identified by whole genome copy number analysis. Clin Cancer Res, 17:1481-1489, 2011

34. Saito M, Schetter AJ, Mollerup S, Kohno T, Skaug V, Bowman ED, Mathe EA, Takenoshita S, Yokota J, Haugen A, Harris CC. The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts. Clin Cancer Res, 17:1875-1882, 2011

35. Yano S, Yamada T, Takeuchi S, Tachibana K, Minami Y, Yatabe Y, Mitsudomi T, Tanaka H, Kimura T, Kudoh S, Nokihara H, Ohe Y, Yokota J, Uramoto H, Yasumoto K, Kiura K, Higashiyama M, Oda M, Saito H, Yoshida J, Kondoh K, Noguchi M. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol, 6:2011-2017, 2011

5. Division of Virology

36. Fujiwara S, Nawa A, Luo C, Kamakura M, Goshima F, Kondo C, Kiyono T, Kikkawa F, Nishiyama Y. Carrier cell-based delivery of replication-competent HSV-1 mutants enhances antitumor effect for ovarian cancer. Cancer Gene Ther, 18:77-86, 2011

37. Ibi M, Zou P, Inoko A, Shiromizu T, Matsuyama M, Hayashi Y, Enomoto M, Mori D, Hirotsune S, Kiyono T, Tsukita S, Goto H, Inagaki M. Trichoplein controls microtubule anchoring at the centrosome by binding to Odf2 and ninein. J Cell Sci, 124:857-864, 2011

38. Kibe T, Kishida M, Kamino M, Iijima M, Chen L, Habu M, Miyawaki A, Hijioka H, Nakamura N, Kiyono T, Kishida S. Immortalization and characterization of normal oral epithelial cells without using HPV and SV40 genes. Oral Science International, 8:20-28, 2011

39. Koga K, Aoki M, Sameshima T, Hamasaki M, Egawa N, Seiki M, Toole BP, Suzumiya J, Nabeshima K. Synthetic emmprin peptides inhibit tumor cell-fibroblast interaction-stimulated upregulation of MMP-2 and tumor cell invasion. Int J Oncol, 39:657-664, 2011

40. Kyo S, Sakaguchi J, Kiyono T, Shimizu Y, Maida Y, Mizumoto Y, Mori N, Nakamura M, Takakura M, Miyake K, Sakamoto M, Inoue M. Forkhead transcription factor FOXO1 is a direct target of progestin to inhibit endometrial epithelial cell growth. Clin Cancer Res, 17:525-537, 2011

41. Matsuyama M, Goto H, Kasahara K, Kawakami Y, Nakanishi M, Kiyono T, Goshima N, Inagaki M. Nuclear Chk1 prevents premature mitotic entry. J Cell Sci, 124:2113-2119, 2011

42. Mizumoto Y, Kyo S, Kiyono T, Takakura M, Nakamura M, Maida Y, Mori N, Bono Y, Sakurai H, Inoue M. Activation of NF-κB is a novel target of KRAS-induced endometrial carcinogenesis. Clin Cancer Res, 17:1341-1350, 2011

43. Shaker M, Yokoyama Y, Mori S, Tsujimoto M, Kawaguchi N, Kiyono T, Nakano T, Matsuura N. Aberrant expression of disintegrin-metalloprotease proteins in the formation and progression of uterine cervical cancer. Pathobiology, 78:149-161, 2011

44. Shiomi K, Kiyono T, Okamura K, Uezumi M, Goto Y, Yasumoto S, Shimizu S, Hashimoto N. CDK4 and cyclin D1 allow human myogenic cells to recapture growth property without compromising differentiation potential. Gene Ther, 18:857-866, 2011

45. Sugimoto N, Yugawa T, Iizuka M, Kiyono T, Fujita M. Chromatin remodeler sucrose nonfermenting 2 homolog (SNF2H) is recruited onto DNA replication origins through interaction with Cdc10 protein-dependent transcript 1 (Cdt1) and promotes pre-replication complex formation. J Biol Chem, 286:39200-39210, 2011

46. Yamato K, Egawa N, Endo S, Ui-Tei K, Yamada T, Saigo K, Hyodo I, Kiyono T, Nakagawa I. Enhanced specificity of HPV16 E6E7 siRNA by RNA-DNA chimera modification. Cancer Gene Ther, 18:587-597, 2011

47. Zushi Y, Narisawa-Saito M, Noguchi K, Yoshimatsu Y, Yugawa T, Egawa N, Fujita M, Urade M, Kiyono T. An in vitro multistep carcinogenesis model for both HPV-positive and -negative human oral squamous cell carcinomas. Am J Cancer Res, 1:869-881, 2011

6. Division of Cancer Development System

48. Endo H, Hosono K, Uchiyama T, Sakai E, Sugiyama M, Takahashi H, Nakajima N, Wada K, Takeda K, Nakagama H, Nakajima A. Leptin acts as a growth factor for colorectal tumours at stages subsequent to tumour initiation in murine colon carcinogenesis. Gut, 60:1363-1371, 2011

49. Ikeda K, Mutoh M, Teraoka N, Nakanishi H, Wakabayashi K, Taguchi R. Increase of oxidant-related triglycerides and phosphatidylcholines in serum and small intestinal mucosa during development of intestinal polyp formation in Min mice. Cancer Sci, 102:79-87, 2011

50. Izumiya M, Tsuchiya N, Okamoto K, Nakagama H. Systematic exploration of cancer-associated microRNA through functional screening assays. Cancer Sci, 102:1615-1621, 2011

51. Kato S, Kubota K, Shimamura T, Shinohara Y, Kobayashi N, Watanabe S, Yoneda M, Inamori M, Nakamura F, Ishiguro H, Nakaigawa N, Nagashima Y, Taguri M, Kubota Y, Goshima Y, Morita S, Endo I, Maeda S, Nakajima A, Nakagama H. Semaphorin 4D, a lymphocyte semaphorin, enhances tumor cell motility through binding its receptor, plexinB1, in pancreatic cancer. Cancer Sci, 102:2029-2037, 2011

52. Takahashi M, Hori M, Mutoh M, Wakabayashi K, Nakagama H. Experimental animal models of pancreatic carcinogenesis for prevention studies and their relevance to human disease. Cancers, 3:582-602, 2011

53. Teraoka N, Mutoh M, Takasu S, Ueno T, Yamamoto M, Sugimura T, Wakabayashi K. Inhibition of intestinal polyp formation by pitavastatin, a HMG-CoA reductase inhibitor. Cancer Prev Res (Phila), 4:445-453, 2011

54. Totsuka Y, Kato T, Masuda S, Ishino K, Matsumoto Y, Goto S, Kawanishi M, Yagi T, Wakabayashi K. In vitro and in vivo genotoxicity induced by fullerene (C₆₀) and kaolin. Genes & Environ, 33:14-20, 2011

55. Tsuchiya N, Izumiya M, Ogata-Kawata H, Okamoto K, Fujiwara Y, Nakai M, Okabe A, Schetter AJ, Bowman ED, Midorikawa Y, Sugiyama Y, Aburatani H, Harris CC, Nakagama H. Tumor suppressor miR-22 determines p53-dependent cellular fate through post-transcriptional regulation of p21. Cancer Res, 71:4628-4639, 2011

56. Uchida S, Watanabe N, Kudo Y, Yoshioka K, Matsunaga T, Ishizaka Y, Nakagama H, Poon RYC, Yamashita K. SCF^βTrCP mediates stress-activated MAPK-induced Cdc25B degradation. J Cell Sci, 124:2816-2825, 2011

57. Uchiyama T, Takahashi H, Endo H, Sugiyama M, Sakai E, Hosono K, Nagashima Y, Inayama Y, Wada K, Hippo Y, Nakajima A. Role of the long form leptin receptor and of the STAT3 signaling pathway in colorectal cancer progression. Int J Oncol, 39:935-940, 2011

58. Wang R, Dashwood WM, Nian H, Löhr CV, Fischer KA, Tsuchiya N, Nakagama H, Ashktorab H, Dashwood RH. NADPH oxidase overexpression in human colon cancers and rat colon tumors induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). Int J Cancer, 128:2581-2590, 2011

59. Wei M, Wanibuchi H, Nakae D, Tsuda H, Takahashi S, Hirose M, Totsuka Y, Tatematsu M, Fukushima S. Low-dose carcinogenicity of 2-amino-3-methylimidazo[4,5-f]quinoline in rats: evidence for the existence of no-effect levels and a mechanism involving p21^{Cip / WAF1}. Cancer Sci, 102:88-94, 2011

60. Yamamoto M, Takahashi-Nakaguchi A, Matsushima-Hibiya Y, Nakano T, Totsuka Y, Imanishi S, Mitsuhashi J, Watanabe M, Nakagama H, Sugimura T, Wakabayashi K. Nucleotide sequence and chromosomal localization of the gene for pierisin-1, a DNA ADP-ribosylating protein, in the cabbage butterfly Pieris rapae. Genetica, 139:1251-1258, 2011

7. Division of Metastasis and Invasion Signaling

61. Uekita T, Sakai R. Roles of CUB domain-containing protein 1 signaling in cancer invasion and metastasis. Cancer Sci, 102:1943-1948, 2011

62. Yagi R, Tanaka M, Sasaki K, Kamata R, Nakanishi Y, Kanai Y, Sakai R. ARAP3 inhibits peritoneal dissemination of scirrhous gastric carcinoma cells by regulating cell adhesion and invasion. Oncogene, 30:1413-1421, 2011

63. Yamaguchi H, Yoshida S, Muroi E, Yoshida N, Kawamura M, Kouchi Z, Nakamura Y, Sakai R, Fukami K. Phosphoinositide 3-kinase signaling pathway mediated by p110α regulates invadopodia formation. J Cell Biol, 193:1275-1288, 2011

8. Division of Molecular and Cellular Medicine

64. Katsuda T, Sakai Y, Ochiya T. Induced pluripotent stem cell-derived hepatocytes as an alternative to human adult hepatocytes. In: Sullivan PJ, Mortensen EK (eds), Induced Stem Cells. USA, Nova Science Publishers, pp 75-103, 2011

65. Kawamata M, Ochiya T. Gene-manipulated embryonic stem cells for rat transgenesis. Cell Mol Life Sci, 68:1911-1915, 2011

66. Kawamata M, Ochiya T. Establishment of embryonic stem cells and generation of genetically modified rats. In: Craig A (ed), Methodological Advances in the Culture. Croatia, InTech, pp 383-396, 2011

67. Mino K, Ozaki M, Nakanishi K, Haga S, Sato M, Kina M, Takahashi M, Takahashi N, Kataoka A, Yanagihara K, Ochiya T, Kamiyama T, Umezawa K, Todo S. Inhibition of nuclear factor-kappaB suppresses peritoneal dissemination of gastric cancer by blocking cancer cell adhesion. Cancer Sci, 102:1052-1058, 2011

68. Murakami Y, Toyoda H, Tanaka M, Kuroda M, Harada Y, Matsuda F, Tajima A, Kosaka N, Ochiya T, Shimotohno K. The progression of liver fibrosis is related with overexpression of the miR-199 and 200 families. PLoS One, 6:e16081, 2011

69. Osaki M, Takeshita F, Sugimoto Y, Kosaka N, Yamamoto Y, Yoshioka Y, Kobayashi E, Yamada T, Kawai A, Inoue T, Ito H, Oshimura M, Ochiya T. MicroRNA-143 regulates human osteosarcoma metastasis by regulating matrix metalloprotease-13 expression. Mol Ther, 19:1123-1130, 2011

70. Takahashi RU, Takeshita F, Fujiwara T, Ono M, Ochiya T. Cancer stem cells in breast cancer. Cancers, 3:1311-1328, 2011

71. Watanabe H, Kominami Y, Gon R, Hayashi M, Nishiki M, Sasaki A, Shiraishi M, Ueda S, Ochiya T, Kamiya K. Trans-differentiation of a duodenal phenotype on duodenal transplantation of different normal tissues in F344 rats. Hiroshima J Med Sci, 60:1-6, 2011

72. Xu D, Takeshita F, Hino Y, Fukunaga S, Kudo Y, Tamaki A, Matsunaga J, Takahashi RU, Takata T, Shimamoto A, Ochiya T, Tahara H. miR-22 represses cancer progression by inducing cellular senescence. J Cell Biol, 193:409-424, 2011

73. Yamamoto Y, Yoshioka Y, Minoura K, Takahashi RU, Takeshita F, Taya T, Horii R, Fukuoka Y, Kato T, Kosaka N, Ochiya T. An integrative genomic analysis revealed the relevance of microRNA and gene expression for drug-resistance in human breast cancer cells. Mol Cancer, 10:135, 2011

9. Division of Cancer Biology

74. Kitamura N, Nakamura Y, Miyamoto Y, Miyamoto T, Kabu K, Yoshida M, Futamura M, Ichinose S, Arakawa H. Mieap, a p53-inducible protein, controls mitochondrial quality by repairing or eliminating unhealthy mitochondria. PLoS One, 6:e16060, 2011

75. Miyamoto Y, Kitamura N, Nakamura Y, Futamura M, Miyamoto T, Yoshida M, Ono M, Ichinose S, Arakawa H. Possible existence of lysosome-like organella within mitochondria and its role in mitochondrial quality control. PLoS One, 6:e16054, 2011

10. Division of Cancer Differentiation

11. Division of Hematological Malignancy

76. Mishima Y, Miyagi S, Saraya A, Negishi M, Endoh M, Endo TA, Toyoda T, Shinga J, Katsumoto T, Chiba T, Yamaguchi N, Kitabayashi I, Koseki H, Iwama A. The Hbo1-Brd1/Brpf2 complex is responsible for global acetylation of H3K14 and required for fetal liver erythropoiesis. Blood, 118:2443-2453, 2011

77. Shima Y, Kitabayashi I. Deregulated transcription factors in leukemia. Int J Hematol, 94:134-141, 2011

78. Yokoyama A, Ficara F, Murphy MJ, Meisel C, Naresh A, Kitabayashi I, Cleary ML. Proteolytically cleaved MLL subunits are susceptible to distinct degradation pathways. J Cell Sci, 124:2208-2219, 2011

12. Division of Pharmacogenomics

13. Division of Pharmacoproteomics

79. Hagiwara T, Saito Y, Nakamura Y, Tomonaga T, Murakami Y, Kondo T. Combined use of a solid-phase hexapeptide ligand library with liquid chromatography and two-dimensional difference gel electrophoresis for intact plasma proteomics. Int J Proteomics, 2011:739615, 2011

80. Kato H, Nishimura T, Ikeda N, Yamada T, Kondo T, Saijo N, Nishio K, Fujimoto J, Nomura M, Oda Y, Lindmark B, Maniwa J, Hibino H, Unno M, Ito T, Sawa Y, Tojo H, Egawa S, Edula G, Lopez M, Wigmore M, Inase N, Yoshizawa Y, Nomura F, Marko-Varga G. Developments for a growing Japanese patient population: facilitating new technologies for future health care. J Proteomics, 74:759-764, 2011

81. Kubota D, Orita H, Yoshida A, Gotoh M, Kanda T, Tsuda H, Hasegawa T, Katai H, Shimada Y, Kaneko K, Kawai A, Kondo T. Pfetin as a prognostic biomarker for gastrointestinal stromal tumor: validation study in multiple clinical facilities. Jpn J Clin Oncol, 41:1194-1202, 2011

82. Mimae T, Tsuta K, Takahashi F, Yoshida a, Kondo T, Murakami Y, Okada M, Takeuchi M, Asamura H, Tsuda H. Steroid receptor expression in thymomas and thymic carcinomas. Cancer, 117:4396-4405, 2011

83. Muto T, Taniguchi H, Kushima R, Tsuda H, Yonemori H, Chen C, Sugihara Y, Sakamoto K, Kobori Y, Palmer H, Nakamura Y, Tomonaga T, Tanaka H, Mizushima H, Fujita S, Kondo T. Global expression study in colorectal cancer on proteins with alkaline isoelectric point by two-dimensional difference gel electrophoresis. J Proteomics, 74:858-873, 2011

84. Suehara Y, Tochigi N, Kubota D, Kikuta K, Nakayama R, Seki K, Yoshida A, Ichikawa H, Hasegawa T, Kaneko K, Chuman H, Beppu Y, Kawai A, Kondo T. Secernin-1 as a novel prognostic biomarker candidate of synovial sarcoma revealed by proteomics. J Proteomics, 74:829-842, 2011

14. Division of Epigenomics

85. Cai LY, Izumi S, Abe M, Imura M, Yasugi T, Wakazono K, Ohnuki Y, Kondo A, Ushijima T. Does aberrant DNA methylation occur in human uterine leiomyomas? An attempt of genome-wide screening by MS-RDA. Tokai J Exp Clin Med, 36:84-90, 2011

86. Colombo F, Falvella FS, Galvan A, Frullanti E, Kunitoh H, Ushijima T, Dragani TA. A 5'-region polymorphism modulates promoter activity of the tumor suppressor gene MFSD2A. Mol Cancer, 10:81, 2011

87. Gyobu K, Yamashita S, Matsuda Y, Igaki H, Niwa T, Oka D, Kushima R, Osugi H, Lee S, Suehiro S, Ushijima T. Identification and validation of DNA methylation markers to predict lymph node metastasis of esophageal squamous cell carcinomas. Ann Surg Oncol, 18:1185-1194, 2011

88. Hattori N, Okochi-Takada E, Kikuyama M, Wakabayashi M, Yamashita S, Ushijima T. Methylation silencing of angiopoietin-like 4 in rat and human mammary carcinomas. Cancer Sci, 102:1337-1343, 2011

89. Hur K, Niwa T, Toyoda T, Tsukamoto T, Tatematsu M, Yang HK, Ushijima T. Insufficient role of cell proliferation in aberrant DNA methylation induction and involvement of specific types of inflammation. Carcinogenesis, 32:35-41, 2011

90. Kuzumaki N, Ikegami D, Tamura R, Hareyama N, Imai S, Narita M, Torigoe K, Niikura K, Takeshima H, Ando T, Igarashi K, Kanno J, Ushijima T, Suzuki T, Narita M. Hippocampal epigenetic modification at the brain-derived neurotrophic factor gene induced by an enriched environment. Hippocampus, 21:127-132, 2011

91. Lee YC, Wang HP, Wang CP, Ko JY, Lee JM, Chiu HM, Lin JT, Yamashita S, Oka D, Watanabe N, Matsuda Y, Ushijima T, Wu MS. Revisit of field cancerization in squamous cell carcinoma of upper aerodigestive tract: better risk assessment with epigenetic markers. Cancer Prev Res, 4:1982-1992, 2011

92. Takeshima H, Yamashita S, Shimazu T, Ushijima T. Effects of genome architecture and epigenetic factors on susceptibility of promoter CpG islands to aberrant DNA methylation induction. Genomics, 98:182-188, 2011

93. Ushijima T, Okochi-Takada E, Takeshima H. Epigenomic analysis in toxicology. In: Casciano DA, Sahu SC (eds), Handbook of Systems Toxicology. U.K., John Wiley & Sons, Ltd., pp 489-507, 2011

94. Ushijima T, Yoshida T. Field cancerization in gastric cancer. In: Dakubo GD (ed), Field Cancerization: Basic Science and Clinical Applications. USA, Nova Science Publishers, pp 187-199, 2011

95. Yoshida T, Yamashita S, Takamura-Enya T, Niwa T, Ando T, Enomoto S, Maekita T, Nakazawa K, Tatematsu M, Ichinose M, Ushijima T. Alu and satα hypomethylation in Helicobacter pylori-infected gastric mucosae. Int J Cancer, 128:33-39, 2011

15. Division of Genome Biology

96. Kohno T, Kunitoh H, Mimaki S, Shiraishi K, Kuchiba A, Yamamoto S, Yokota J. Contribution of the TP53, OGG1, CHRNA3, and HLA-DQA1 genes to the risk for lung squamous cell carcinoma. J Thorac Oncol, 6:813-817, 2011

97. Kozu Y, Tsuta K, Kohno T, Sekine I, Yoshida A, Watanabe S, Tamura T, Yokota J, Suzuki K, Asamura H, Furuta K, Tsuda H. The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma. Lung Cancer, 73:45-50, 2011

98. Li S, Kanno S, Watanabe R, Ogiwara H, Kohno T, Watanabe G, Yasui A, Lieber MR. Polynucleotide kinase and aprataxin-like forkhead-associated protein (PALF) acts as both a single-stranded DNA endonuclease and a single-stranded DNA 3' exonuclease and can participate in DNA end joining in a biochemical system. J Biol Chem, 286:36368-36377, 2011

99. Ogiwara H, Kohno T. Essential factors for incompatible DNA end joining at chromosomal DNA double strand breaks in vivo. PLoS One, 6:e28756, 2011

100. Ogiwara H, Ui A, Otsuka A, Satoh H, Yokomi I, Nakajima S, Yasui A, Yokota J, Kohno T. Histone acetylation by CBP and p300 at double-strand break sites facilitates SWI/SNF chromatin remodeling and the recruitment of non-homologous end joining factors. Oncogene, 30:2135-2146, 2011

101. Yamauchi M, Yoshino I, Yamaguchi R, Shimamura T, Nagasaki M, Imoto S, Niida A, Koizumi F, Kohno T, Yokota J, Miyano S, Gotoh N. N-cadherin expression is a potential survival mechanism of gefitinib-resistant lung cancer cells. Am J Cancer Res, 1:823-833, 2011

102. Yoshida A, Tsuta K, Nitta H, Hatanaka Y, Asamura H, Sekine I, Grogan TM, Fukayama M, Shibata T, Furuta K, Kohno T, Tsuda H. Bright-field dual-color chromogenic in situ hybridization for diagnosing echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinomas. J Thorac Oncol, 6:1677-1686, 2011

16. Division of Cancer Genomics

103. Hasebe T, Iwasaki M, Akashi-Tanaka S, Hojo T, Shibata T, Kinoshita T, Tsuda H. Important histologic outcome predictors for patients with invasive ductal carcinoma of the breast. Am J Surg Pathol, 35:1484-1497, 2011

104. Hasebe T, Iwasaki M, Akashi-Tanaka S, Hojo T, Shibata T, Sasajima Y, Kinoshita T, Tsuda H. Atypical tumor-stromal fibroblasts in invasive ductal carcinoma of the breast. Am J Surg Pathol, 35:325-336, 2011

105. Hasebe T, Iwasaki M, Akashi-Tanaka S, Hojo T, Shibata T, Sasajima Y, Kinoshita T, Tsuda H. Modified primary tumour/vessel tumour/nodal tumour classification for patients with invasive ductal carcinoma of the breast. Br J Cancer, 105:698-708, 2011

106. Hasebe T, Iwasaki M, Akashi-Tanaka S, Hojo T, Shibata T, Sasajima Y, Kinoshita T, Tsuda H. Prognostic significance of mitotic figures in metastatic mammary ductal carcinoma to the lymph nodes. Hum Pathol, 42:1823-1832, 2011

107. Miyamoto M, Ojima H, Iwasaki M, Shimizu H, Kokubu A, Hiraoka N, Kosuge T, Yoshikawa D, Kono T, Furukawa H, Shibata T. Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma. Br J Cancer, 105:131-138, 2011

108. Shibata T, Kokubu A, Miyamoto M, Sasajima Y, Yamazaki N. Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation. Am J Pathol, 178:1395-1402, 2011

109. Shibata T, Kokubu A, Saito S, Narisawa-Saito M, Sasaki H, Aoyagi K, Yoshimatsu Y, Tachimori Y, Kushima R, Kiyono T, Yamamoto M. NRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer. Neoplasia, 13:864-873, 2011

110. Shirakihara T, Horiguchi K, Miyazawa K, Ehata S, Shibata T, Morita I, Miyazono K, Saitoh M. TGF-β regulates isoform switching of FGF receptors and epithelial-mesenchymal transition. EMBO J, 30:783-795, 2011

111. Sugawara W, Arai Y, Kasai F, Fujiwara Y, Haruta M, Hosaka R, Nishida K, Kurosumi M, Kobayashi Y, Akagi K, Kaneko Y. Association of germline or somatic TP53 missense mutation with oncogene amplification in tumors developed in patients with Li-Fraumeni or Li-Fraumeni-like syndrome. Genes Chromosomes Cancer, 50:535-545, 2011

112. Totoki Y, Tatsuno K, Yamamoto S, Arai Y, Hosoda F, Ishikawa S, Tsutsumi S, Sonoda K, Totsuka H, Shirakihara T, Sakamoto H, Wang L, Ojima H, Shimada K, Kosuge T, Okusaka T, Kato K, Kusuda J, Yoshida T, Aburatani H, Shibata T. High-resolution characterization of a hepatocellular carcinoma genome. Nat Genet, 43:464-469, 2011

113. Watanabe T, Chuma S, Yamamoto Y, Kuramochi-Miyagawa S, Totoki Y, Toyoda A, Hoki Y, Fujiyama A, Shibata T, Sado T, Noce T, Nakano T, Nakatsuji N, Lin H, Sasaki H. MITOPLD is a mitochondrial protein essential for nuage formation and piRNA biogenesis in the mouse germline. Dev Cell, 20:364-375, 2011

114. Watanabe T, Tomizawa S, Mitsuya K, Totoki Y, Yamamoto Y, Kuramochi-Miyagawa S, Iida N, Hoki Y, Murphy PJ, Toyoda A, Gotoh K, Hiura H, Arima T, Fujiyama A, Sado T, Shibata T, Nakano T, Lin H, Ichiyanagi K, Soloway PD, Sasaki H. Role for piRNAs and noncoding RNA in de novo DNA methylation of the imprinted mouse Rasgrf1 locus. Science, 332:848-852, 2011

115. Yoshida A, Tsuta K, Nakamura H, Kohno T, Takahashi F, Asamura H, Sekine I, Fukayama M, Shibata T, Furuta K, Tsuda H. Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol, 35:1226-1234, 2011

17. Division of Cancer Pathophysiology

116. Ando Y, Hojo M, Kanaide M, Takada M, Sudo Y, Shiraishi S, Sumikawa K, Uezono Y. S(+)-Ketamine suppresses desensitization of γ-aminobutyric acid type B receptor-mediated signaling by inhibition of the interaction of γ-aminobutyric acid type B receptors with G protein-coupled receptor kinase 4 or 5. Anesthesiology, 114:401-411, 2011

117. Fujitsuka N, Asakawa A, Uezono Y, Minami K, Yamaguchi T, Niijima A, Yada T, Maejima Y, Sedbazar U, Sakai T, Hattori T, Kase Y, Inui A. Potentiation of ghrelin signaling attenuates cancer anorexia–cachexia and prolongs survival. Transl Psychiatry, 1:e23, 2011

118. Imai S, Sudo Y, Nakamura A, Ozeki A, Asato M, Hojo M, Devi LA, Kuzumaki N, Suzuki T, Uezono Y, Narita M. Possible involvement of β-endorphin in a loss of the coordinated balance of μ-opioid receptors trafficking processes by fentanyl. Synapse, 65:962-966, 2011

119. Minami K, Sudo Y, Yokoyama T, Ogata J, Takeuchi M, Uezono Y. Sevoflurane inhibits the µ-opioid receptor function expressed in Xenopus oocytes. Pharmacology, 88:127-132, 2011

120. Minami K, Yokoyama T, Ogata J, Uezono Y. The tramadol metabolite O-desmethyl tramadol inhibits substance P-receptor functions expressed in Xenopus oocytes. J Pharmacol Sci, 115:421-424, 2011

121. Narita M, Niikura K, Nanjo-Niikura K, Narita M, Furuya M, Yamashita A, Saeki M, Matsushima Y, Imai S, Shimizu T, Asato M, Kuzumaki N, Okutsu D, Miyoshi K, Suzuki M, Tsukiyama Y, Konno M, Yomiya K, Matoba M, Suzuki T. Sleep disturbances in a neuropathic pain-like condition in the mouse are associated with altered GABAergic transmission in the cingulate cortex. Pain, 152:1358-1372, 2011

122. Suzuki M, El-Hage N, Zou S, Hahn YK, Sorrell ME, Sturgill JL, Conrad DH, Knapp PE, Hauser KF. Fractalkine/CX₃CL1 protects striatal neurons from synergistic morphine and HIV-1 Tat-induced dendritic losses and death. Mol Neurodegener, 6:78, 2011

123. Yanagita T, Satoh S, Uezono Y, Matsuo K, Nemoto T, Maruta T, Yoshikawa N, Iwakiri T, Minami K, Murakami M. Transcriptional up-regulation of cell surface Na_V 1.7 sodium channels by insulin-like growth factor-1 via inhibition of glycogen synthase kinase-3β in adrenal chromaffin cells: enhancement of ²²Na⁺ influx, ⁴⁵Ca²⁺ influx and catecholamine secretion. Neuropharmacology, 61:1265-1274, 2011

124. Yokoyama T, Minami K, Sudo Y, Horishita T, Ogata J, Yanagita T, Uezono Y. Effects of sevoflurane on voltage-gated sodium channel Na_v1.8, Na_v1.7, and Na_v1.4 expressed in Xenopus oocytes. J Anesth, 25:609-613, 2011

125. Yokoyama T, Ohbuchi T, Saito T, Sudo Y, Fujihara H, Minami K, Nagatomo T, Uezono Y, Ueta Y. Allyl isothiocyanates and cinnamaldehyde potentiate miniature excitatory postsynaptic inputs in the supraoptic nucleus in rats. Eur J Pharmacol, 655:31-37, 2011

18. Division of Cancer Stem Cell

126. Ando Y, Maida Y, Morinaga A, Burroughs AM, Kimura R, Chiba J, Suzuki H, Masutomi K, Hayashizaki Y. Two-step cleavage of hairpin RNA with 5' overhangs by human DICER. BMC Mol Biol, 12:6, 2011

127. Jinushi M, Chiba S, Yoshiyama H, Masutomi K, Kinoshita I, Dosaka-Akita H, Yagita H, Takaoka A, Tahara H. Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. Proc Natl Acad Sci U S A, 108:12425-12430, 2011

128. Kawashima M, Kawakita T, Maida Y, Kamoi M, Ogawa Y, Shimmura S, Masutomi K, Tsubota K. Comparison of telomere length and association with progenitor cell markers in lacrimal gland between Sjögren syndrome and non-Sjögren syndrome dry eye patients. Mol Vis, 17:1397-1404, 2011

129. Maida Y, Masutomi K. RNA-dependent RNA polymerases in RNA silencing. Biol Chem, 392:299-304, 2011

130. Okamoto N, Yasukawa M, Nguyen C, Kasim V, Maida Y, Possemato R, Shibata T, Ligon KL, Fukami K, Hahn WC, Masutomi K. Maintenance of tumor initiating cells of defined genetic composition by nucleostemin. Proc Natl Acad Sci U S A, 108:20388-20393, 2011

131. Rosenbluh J, Nijhawan D, Chen Z, Wong KK, Masutomi K, Hahn WC. RMRP is a non-coding RNA essential for early murine development. PLoS One, 6:e26270, 2011

19. Division of Gene and Immune Medicine

132. Narumi K, Aoki K. Combination of immune gene therapy with allogeneic hematopoietic stem cell transplantation against solid cancers. In: Kwak JY, Han JY (eds), Cellular and Genetic Practices for Translational Medicine. India, Research Signpost, pp 227-245, 2011

20. Division of Genome Stability Research

133. Atsumi Y, Fujimori H, Fukuda H, Inase A, Shinohe K, Yoshioka Y, Shikanai M, Ichijima Y, Unno J, Mizutani S, Tsuchiya N, Hippo Y, Nakagama H, Masutani M, Teraoka H, Yoshioka K. Onset of quiescence following p53 mediated down-regulation of H2AX in normal cells. PLoS One, 6:e23432, 2011

134. Khan MMG, Ryden AM, Chowdhury MS, Hasan MA, Kazi JU. Maximum likelihood analysis of mammalian p53 indicates the presence of positively selected sites and higher tumorigenic mutations in purifying sites. Gene, 483:29-35, 2011

21. Division of Chemotherapy and Clinical Research

135. Ito H, Honda K, Satow R, Arai E, Shitashige M, Ono M, Sakuma T, Sakano S, Naito K, Matsuyama H, Yamada T. Combined functional genome survey of therapeutic targets for clear cell carcinoma of the kidney. Jpn J Clin Oncol, 41:847-853, 2011

136. Matsubara J, Honda K, Ono M, Sekine S, Tanaka Y, Kobayashi M, Jung G, Sakuma T, Nakamori S, Sata N, Nagai H, Ioka T, Okusaka T, Kosuge T, Tsuchida A, Shimahara M, Yasunami Y, Chiba T, Yamada T. Identification of adipophilin as a potential plasma biomarker for colorectal cancer using label-free quantitative mass spectrometry and protein microarray. Cancer Epidemiol Biomarkers Prev, 20:2195-2203, 2011

137. Matsubara J, Honda K, Ono M, Tanaka Y, Kobayashi M, Jung G, Yanagisawa K, Sakuma T, Nakamori S, Sata N, Nagai H, Ioka T, Okusaka T, Kosuge T, Tsuchida A, Shimahara M, Yasunami Y, Chiba T, Hirohashi S, Yamada T. Reduced plasma level of CXC chemokine ligand 7 in patients with pancreatic cancer. Cancer Epidemiol Biomarkers Prev, 20:160-171, 2011

138. Murakoshi Y, Honda K, Sasazuki S, Ono M, Negishi A, Matsubara J, Sakuma T, Kuwabara H, Nakamori S, Sata N, Nagai H, Ioka T, Okusaka T, Kosuge T, Shimahara M, Yasunami Y, Ino Y, Tsuchida A, Aoki T, Tsugane S, Yamada T. Plasma biomarker discovery and validation for colorectal cancer by quantitative shotgun mass spectrometry and protein microarray. Cancer Sci, 102:630-638, 2011

139. Shitashige M, Yamada T. Targeting of Wnt signaling inside the nucleus. In: Gross KH, Kahn M (eds), Targeting the Wnt Pathway in Cancer. USA, Springer, pp 211-225, 2011

22. Central Animal Division

140. Hori M, Kitahashi T, Imai T, Ishigamori R, Takasu S, Mutoh M, Sugimura T, Wakabayashi K, Takahashi M. Enhancement of carcinogenesis and fatty infiltration in the pancreas in N-nitrosobis(2-oxopropyl)amine-treated hamsters by high-fat diet. Pancreas, 40:1234-1240, 2011

141. Kitahashi T, Yoshimoto M, Imai T. Novel immunohistochemical marker, integrin α_vβ₃, for BOP-induced early lesions in hamster pancreatic ductal carcinogenesis. Oncol Lett, 2:229-234, 2011

142. Koyama N, Yasui M, Kimura A, Takami S, Suzuki T, Masumura K, Nohmi T, Masuda S, Kinae N, Matsuda T, Imai T, Honma M. Acrylamide genotoxicity in young versus adult gpt delta male rats. Mutagenesis, 26:545-549, 2011

23. Central Radioisotope Division

24. Core Facility Division

25. Division of Refractory Cancer Research

143. Ozeki C, Sawai Y, Shibata T, Kohno T, Okamoto K, Yokota J, Tashiro F, Tanuma S, Sakai R, Kawase T, Kitabayashi I, Taya Y, Ohki R. Cancer susceptibility polymorphism of p53 at codon 72 affects phosphorylation and degradation of p53 protein. J Biol Chem, 286:18251-18260, 2011

26. Division of Cancer Prevention Research

144. Fujii G, Yamamoto M, Takahashi M, Mutoh M. Role of adpicytokines in colorectal carcinogenesis. Curr Res in Cancer, 5:39-48, 2011

145. Mutoh M, Teraoka N, Takasu S, Takahashi M, Onuma K, Yamamoto M, Kubota N, Iseki T, Kadowaki T, Sugimura T, Wakabayashi K. Loss of adiponectin promotes intestinal carcinogenesis in Min and wild-type mice. Gastroenterology, 140:2000-2008, 2011

146. Teraoka N, Mutoh M, Takasu S, Ueno T, Nakano K, Takahashi M, Imai T, Masuda S, Sugimura T, Wakabayashi K. High susceptibility to azoxymethane-induced colorectal carcinogenesis in obese KK-A^y mice. Int J Cancer, 129:528-535, 2011

27. Division of Integrative Omics and Bioinformatics

147. Katoh M. Network of WNT and other regulatory signaling cascades in pluripotent stem cells and cancer stem cells. Curr Pharm Biotechnol, 12:160-170, 2011

148. Qi DL, Ohhira T, Fujisaki C, Inoue T, Ohta T, Osaki M, Ohshiro E, Seko T, Aoki S, Oshimura M, Kugoh H. Identification of PITX1 as a TERT suppressor gene located on human chromosome 5. Mol Cell Biol, 31:1624-1636, 2011